In this prospective , controlled , single-centre study , 50 eyes of 50 patients ( mean age : 74.1 7.1 ; median 74 ( 69/78 ) ) with ARMD were enrolled and randomized 1:1 to group 1 - core vitrectomy additional to three times injections of ranibizumab ( 3x Rbz ) and Group 2 - 3x Rbz ( control ) .